CDEK by Data4ThePeople

Sign in Sign up

← All organizations

ViaCyte

For profitWebsite ↗

Also known as: Novocell | ViaCyte | ViaCyte, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 2

First clinical trial

Last known activity

Nov 30, 2022

Acquired by Vertex → Henry Schein, Inc → Watson Pharmaceuticals → Actavis → Allergan PLC (2015) → AbbVie on Jul 11, 2022

Timeline

1990s

Jun 1, 1999
ViaCyte— Founded

2010s

Jun 26, 2019
AbbVie— Now

2020s

Jul 11, 2022
Vertex— Acquired By

Drugs by trial phase (4 distinct, 6 trials)

Phase 2 (3 own, 0 via acquisition)

Phase 1 (1 own, 0 via acquisition)

vctx210a

Indications

Studied for

Recent trials (9)

NCT05565248CollaboratorPhase 1/Phase 2Nov 30, 2022
NCT05565248Study directorPhase 1/Phase 2Nov 30, 2022
NCT05210530CollaboratorPhase 1Jan 24, 2022
NCT05210530Study directorPhase 1Jan 24, 2022
NCT04678557Lead sponsorPhase 1/Phase 2Jun 25, 2019
NCT04678557Overall official - principal investigatorPhase 1/Phase 2Jun 25, 2019
NCT03163511Lead sponsorPhase 1/Phase 2Jun 1, 2017
NCT03162926Lead sponsorPhase 1Jun 1, 2017
NCT00260234Lead sponsorPhase 1/Phase 2Nov 1, 2005

Details

Founded: San Diego, CA, US Jun 1, 1999
Last known activity: Nov 30, 2022